Druck Icon

Eckert & Ziegler: PENTIXAPHARM Lead Candidate PENTIXAFOR Can Go in Phase III Study, EMA says

Insider information pursuant to Article 17 MAR

Berlin, 04.02.2021 - Würzburg based PENTIXAPHARM GmbH, an associate of Eckert & Ziegler AG (ISIN DE0005659700), has received confirmation from the European Medicines Agency (EMA) that its lead candidate PENTIXAFOR may be tested directly in a phase III clinical study. The agency said that there are "sufficient safety data available to initiate a phase III trial" for the Gallium-68 labelled radiodiagnostic which detects CXCR4-positiv solid tumors and CXCR4-positive hematological malignancies.


Eckert & Ziegler AG
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel. +49 30 941084-138, karolin.riehle@dont-want-spam.ezag.de, www.ezag.de

Information and Explanation of the Issuer to this News:

Details about PENTIXAFOR and the content of the EMA advice will be provided in the next days in a separate PENTIXAPHARM press release.